BusinessMelinta Therapeutics Updates Pyrrolocytosine and Enhanced Macrolide Programs at ECCMID Showcasing Company’s Structure-Based Drug DesignBy Nasdaq OMXApr 21, 2017, 1:56 PM UTC
BusinessMelinta Therapeutics Presentations at ECCMID Show Potential of Baxdela in Obese and other Challenging Patient TypesBy Nasdaq OMXApr 21, 2017, 1:37 PM UTC
